Core Alternative Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Core Alternative Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4	Closed	-$2.25K	–	316
2025 Q3	$2.25K	Sell	4 -39	-91%	-$22.1K	﹤0.01%	237
2025 Q2	$22.6K	Hold	43	–	–	0.01%	163
2025 Q1	$27.3K	Hold	43	–	–	0.01%	160
2024 Q4	$30.6K	Hold	43	–	–	0.01%	170
2024 Q3	$45.2K	Hold	43	–	–	0.01%	149
2024 Q2	$45.2K	Hold	43	–	–	0.01%	151
2024 Q1	$41.4K	Sell	43 -12	-22%	-$11.4K	0.01%	152
2023 Q4	$48.3K	Sell	55 -6	-10%	-$4.94K	0.01%	170
2023 Q3	$50.2K	Hold	61	–	–	0.01%	181
2023 Q2	$43.8K	Buy	61 +2	+3%	+$1.54K	0.01%	157
2023 Q1	$48.5K	Buy	59 +8	+16%	+$6.03K	0.01%	160
2022 Q4	$36.8K	Buy	51 +1	+2%	+$738	﹤0.01%	176
2022 Q3	$34K	Buy	50 +3	+6%	+$1.89K	0.01%	173
2022 Q2	$28K	Buy	47 +11	+31%	+$7.15K	0.01%	193
2022 Q1	$25K	Buy	36 +32	+800%	+$20.2K	0.01%	198
2021 Q4	$3K	Buy	+4	New	+$2.46K	﹤0.01%	255

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Core Alternative Capital's REGN Position: Q4 2025 in Review

Core Alternative Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 4 shares — an estimated $2.25K sold.

Core Alternative Capital first reported a position in REGN in Q4 2021 and held it in 16 quarters. The position peaked at $50.2K in Q3 2023. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Core Alternative Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Core Alternative Capital sold 4 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $2.25K.
Core Alternative Capital first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 16 quarters.
Core Alternative Capital's Regeneron Pharmaceuticals position peaked at $50.2K in Q3 2023.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Core Alternative Capital's 13F filing for Q4 2025, filed 2 Feb 2026.